Plethico Pharmaceuticals (Delisted) share news and announcements

BSE: 532739

Last traded ₹9.05 on 13 Jun 2016

Delisted on 11 May 2018.

Plethico Pharmaceuticals share news and announcements

488 announcements, routine notices left out, newest first. Page 10 of 10.

  1. May 2008

    • 20 May · Board meeting

      To consider the following business: 1) To fix day, date and venue of Annual General Meeting of the Company. 2) To approve the draft notice of Annual General Meeting. 3) To recommend Dividend for the FY 2006-2007. 4) To consider, approve and take on record the Directors' Report, Auditors Report and audited financial statements and Corporate Governance Report of the Company. 5) any other matter with the permission of Chair.

  2. Apr 2008

    • 28 Apr · Business

      Press release towards summary of the financial performance of the Company for the quarter ended on March 31, 2008. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 21 Apr · Board meeting

      To consider, approve and take on record the Quarterly Un-audited Financial Results of the Company for the quarter ended on March 31, 2008 and any other matter with the permission of Chair.

    • 2 Apr · Board meeting

      Board of Directors of the Company at its meeting held on March 28, 2008 has approved the following : 1) Audited financial results of the Company for the quarter and 15 months accounting period ended on December 31, 2007. 2) Re-appointment of Shri Shashikant Patel and Shri Chirag Patel as Chairman & Managing Director and Whole-time Director & Chief Executive Officer of the Company respectively for a further period of 3 years w.e.f. April 01, 2008 at a remuneration as may be decided by the Board of Directors within the limits prescribed under Schedule XIII of the Companies Act, 1956 and Subject to approval of members of the Company at the General Meeting of the Company.

  3. Mar 2008

    • 28 Mar · Business

      Press release towards summary of the financial performance of the Company for the quarter and 15 months accounting period ended on December 31, 2007. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 28 Mar · Management

      The Board of Directors of the Company at its meeting held on March 28, 2008 has approved the following: 1) Re-appointment of Shri Shashikant Patel and Shri Chirag Patel as Chairman & Managing Director and Whole-time Director & Chief Executive Officer of the Company respectively for a further period of 3 years w.e.f. 01.04.2008 at a remuneration as may be decided by the Board of Directors within the limits prescribed under Schedule XIII of the Companies Act, 1956 and subject to approval of members of the Company at the General Meeting of the Company.

    • 18 Mar · Board meeting

      To consider interalia audited financial results of the Company for the period/accounting year ended on December 31, 2007.

    • 7 Mar · Updates

      The manufacturing unit of the Company situated at Kandla Special Economic Zone has been awarded with the "Top Exporter Award" for the year 2006-07 for Chemicals, Drugs, Pharmaceuticals & Allied Sector by the Office of Development Commissioner, Kandla Special Economic Zone, Ministry of Commerce and Industry. The Top Exporter award has been received on behalf of the Company by Shri Hemant Modi, Chief Operating Officer of the Company at the 43rd Foundation Day celebrations on 7th March, 2008.

  4. Feb 2008

    • 19 Feb · Change in Compliance Officer / Others

      The Board of Directors of the Company at its meeting held on 19.02.2008 has approved the following: (1) setting-up of State-of-the-Art manufacturing facility in the Dubai UAE (Middle East) through the wholly owned subsidiary (proposed name - Plethico International Limited) for the medical lozenges, NDDS Tablets/Capsules, Confectionary and allied products to cater the demand of the high volume emerging markets throughout the world. (2) Change in Compliance Officer of the company

    • 19 Feb · Updates

      Company's medicated lozenges and confectionery has always been a high revenue-earning generator and has been growing at a very fast space for all the markets including India. Due to tremendous growth in demand of the aforesaid segment, the company is facing capacity crunch and in view of this company is evaluating the best proposal location for this state-of-the-art manufacturing facility. The further details on the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 19 Feb · Management

      Mr. Ashok Mishra has been appointed as the "Company Secretary" and "Compliance Officer" of the Company w.e.f. 16/02/2008 in place of Mr. Pankaj Pabaiya, who has resigned from the Company w.e.f. 16/02/2008

  5. Jan 2008

    • 14 Jan · Results

      The Company will publish the Quarterly/Yearly Audited Financial Results for the last quarter/year ending on 31st December, 2007, within a period of 3 months i.e. upto 31st March, 2008

    • 2 Jan · Business

      Press release, titled "Plethico Pharmaceuticals Limited Completes Acquisition of Natrol, Inc.". A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

  6. Nov 2007

    • 23 Nov · Management

      Mr. Ashok Sodhani, Non Executive Independent Director of the Company resigned from the Board of Directors of the Company with effect from 22nd November, 2007.

    • 19 Nov · Business

      Press release dated November 18, 2007, titled "Plethico Pharmaceuticals Limited to acquire USA's Natrol, Inc.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

  7. Oct 2007

    • 31 Oct · Business

      Press release dated October 31, 2007, titled " Plethico Pharmaceuticals Ltd. - Summary of Financial Performance for Quarter IV, 2006-07". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 19 Oct · Board meeting

      To consider, approve and take on record the Quarterly Unaudited Financial Results of the Company for the quarter ended on September 30, 2007 and any other matter with the permission of Chair.

    • 16 Oct · Issue of Foreign Currency Convertible Bonds

      Vide its letter dated October 16, 2007, that: "Plethico Pharmaceuticals Limited today announced that it has successfully priced an offering of US$ 75 million by issue of foreign currency convertible bonds. The bonds have a zero coupon with tenor of 5 years and 1 day and are convertible into equity shares at a premium of 35% over the reference share price of Rs.447.95 (Closing price of the Shares on the National Stock Exchange Limited on October 15, 2007). Citigroup acted as the sole bookrunner to the transaction".

    • 1 Oct · Extension of Financial Year / Others

      Outcome of the Board Meeting held on October 01, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

  8. Sep 2007

    • 4 Sep · Change in Corporate Office

      The Company has shifted its Corporate Office to new location situated at :- "Sabnam House", Plot No. A/15-16, Cross Road No.2, MIDC, Andheri (E), Mumbai-400093; Phone No. : 91-022-66988301; Fax No. : 91-022-66988300 with immediate effect

  9. Jul 2007

    • 18 Jul · Utilisation of Funds

      Details of utilizations of fund. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 18 Jul · Business

      Press release dated July 18, 2007, titled " Plethico Pharmaceuticals Ltd. - Summary of Financial Performance for Quarter III, 2006-07". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 9 Jul · Board meeting

      To consider, approve and take on record the Quarterly Unaudited Financial Results of the Company for the quarter ended on June 30, 2007 and any other matter with the permission of Chair.

  10. Apr 2007

    • 18 Apr · Utilisation of Funds

      Details of utilizations of fund. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 17 Apr · Business

      Company has taken the following decision: That the company plans to do a possible acquisition in Germany in the Herbal segment. This will help the Company to strengthen the Herbal focus of the Company and also enable the marketing of herbal preparations in the Advanced Countries.

    • 12 Apr · Business

      Company has taken following decision: 1) The company has appointed M/s. Singhi Advisors Ltd. (formerly Singhi & Associates) as company's M&A Advisors on a Global level. The address of M/s. Sindhi Advisors is as under: 903, Raheja Centre, Nariman Point, Mumbai - 400 021, India. 2) The Company plans to do a possible acquisition of a minority stake in a CIS based retail pharmacy Chain Company. This acquisition will enable the company to de-basket it's credit risks in CIS and help move from Credit Market (distribution) to a Cash Market Segment (Retail Pharmacy).

    • 11 Apr · Board meeting

      To consider, approve and take on record the Quarterly Unaudited Financial Results of the Company for the quarter ended on March 31, 2007 and any other matter with the permission of the Chair.

  11. Mar 2007

    • 30 Mar · Miscellaneous

      Chairman's Speech at the Annual General Meeting held on March 30, 2007. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 30 Mar · Meeting

      The 14th Annual General Meeting of the members of the Company held on Friday the 30th day of March 2007 at the Registered office of the Company and following decisions have been taken :- (1) Company has declared the dividend for the year 2005-06 of Rs. 2.50 per equity share i.e. @25%. (2) Mr. Ashok Sodhani, Dr. G.N. Qazi, Mr. Pramod K. Shrivastava and Mr. Abhay Suhane are appointed as Director of the Company. (3) The Board of Directors of the Company is authorized to decide sitting fees for attending the board meetings /compensation payable for professional services rendered by the Non-Executive Independent Directors to the Company. (4) Revision in the remuneration and benefits payable to Shri Shashikant Patel Chairman cum managing Director of the Company effective from 1st day of January, 2007 for the remaining part of his tenure till 31st March, 2008. (5) Revision in the remuneration and benefits payable to Shri Chirag Patel, Whole-Time Director & Chief Executive Officer of the Company effective from 1st day of January, 2007 for the remaining part of his tenure till 31st March, 2008. (6) Board of Directors is authorized to finalize the proposals related to acquisition of Retail Pharmacy chain and/or Manufacturing Unit and/or OTC Brand and/or Marketing Firms etc. in the US markets requiring total investment no exceeding Rs. 400 Crores by fulfilling all the formalities as required to be complied with under different Acts as are in force. (7) Unutilized portion of IPO proceeds up to maximum extent of Rs. 35 Crores be utilized by the company for company's proposals related to acquisition of Retail Pharmacy Chain and/or Manufacturing Unit and/or OTC Brand and/or Marketing Firms etc. in the US Markets. (8) Company is authorized to issue Foreign Convertible Currency Bond (FCCB) not exceeding US$ 75 million (approx. Rs. 330 crores), subject to however compliance of applicable rules, regulations and guidelines as issued by the Reserve Bank of India or all other regulatory authorities from time to time as well as compliance of applicable provisions of the Foreign Exchange Management Act, 1999. It will be used to finance the proposal related to acquisition of Retail Pharmacy Chain and/or Manufacturing Unit and/or OTC Band and/or Marketing Firms etc. in the US Markets.

    • 12 Mar · Miscellaneous

      Meeting of the Board of Directors of the Company convened at a short notice, held on March 12, 2007 considered the proposals and following decision have been taken:- The equity holding in six subsidiary companies in CIS countries be partly hived off, out of equity held by the company in proportion stated hereunder at a premium of 40% over company's cost of acquisition, on the terms and conditions and on the consideration as set forth in the draft agreement, the draft of which was approved by the Board and initialed by the Chairman for the purpose of the identification. (1) Name of the Company:- TOO REZLOV LTD; Country:- KAZAKHSTAN; Equity holding to be transferred:- 30% of the paid up capital, (2) Name of the Company:- ICS REZLOV-MO,SRL; Country:- MOLDOVA; Equity holding to be transferred:- 30% of the paid up capital, (3) Name of the Company:- OOO REZLOV LTD; Country:- KYRGHYZSTAN; Equity holding to be transferred:- 30% of the paid up capital, (4) Name of the Company:- CJSC REZLOV; Country:- RUSSIA; Equity holding to be transferred:- 06% of the paid up capital, (5) Name of the Company:- SC REZLOV; Country:- UKRAINE; Equity holding to be transferred:- 06% of the paid up capital, (6) Name of the Company:- REZLOV LLS; Country:- AZERBEIJAN; Equity holding to be transferred:- 06% of the paid up capital.

    • 5 Mar · Dividend

      Dividends, if sanctioned by the Members at the Annual General Meeting will be payable on and after 30.03.2007.

  12. Feb 2007

    • 26 Feb · Meeting

      The Board of Directors at their meeting held on Monday the 26th day of February, 2007 considered the proposals and following decision were taken:- 1) that the Register of Members and Share Transfer Books will remain closed from 27.03.2007 to 30.03.2007 (both days inclusive) for the purpose of distribution of dividend to the members for the year ended on 30.09.2006; 2) that the 14th Annual General Meeting of the members of the Company for the year ended on 30.09.2006 scheduled to be held on Friday the 30th day of March 2007 at the Registered Office of the company at 9.30 A.M; 3) that subject to the approval of the members in the forthcoming Annual General Meeting, Foreign Currency Convertible Bond (FCCB) not exceeding US$ 75 Millions be issued to finance Company's project related to acquisition of Retail Pharmacy Chain and/or Manufacturing Unit and/or OTC Brand and/or Marketing Firms etc. in US Market; and 4) that subject to the approval of the members in the forthcoming Annual General Meeting, the unutilized portion of IPO proceeds to the extent of Rs. 35.00 Crores be utilized by the Company for the purpose of acquiring Retail Pharmacy Chain and/or Manufacturing Unit and/or OTC Brand and/or Marketing Firms etc. in US Market and the projects specified in the Prospectus dated 19.04.2006 not as yet implemented are now to be completed out of internal accruals and/or bank finance and/or any other finance option then available. This modification is recommended in order to maximize return on investment. Accordingly the Board has recommended that out of total IPO proceeds of Rs. 110 Crores, Rs. 75.00 Crores are to be utilized for different projects specified in the prospectus dated 19.04.2006 and related IPO expenses and balance of Rs. 35 Crores for the acquisition of Retail Pharmacy Chain and/or Manufacturing Unit and/or OTC Brand and/or Marketing Firms etc. in US Market

    • 19 Feb · Board meeting

      To transact the following businesses:- 1) To decide the date of Book Closure for the purpose of distribution of dividend to the members for the year ended on September 30,2006; 2) To consider and approve the draft Director's Report & Report on Corporate Governance; 3) To consider the proposal for revision of Salary of the executive directors; 4) To consider the payment of sitting fees to all non-executive directors; 5) To decide the date of Annual General Meeting for the year ended on September 30,2006 and to approve the draft notice for the same; and 6) Any other matter with the permission of the chair.

  13. Jan 2007

    • 30 Jan · Utilisation of Funds

      The Status of utilization of IPO proceed upto 31.12.2006 is as under (Rs. in Crores) : (1) Proposed utilization as per prospectus :- Capital expenditure on different projects; Estimated cost Rs. in crores :- 117.17; Expenditure incurred up to 31.12.2006 Rs. in crores :- 33.48, (2) Proposed utilization as per prospectus :- Working Capital Requirement; Estimated cost Rs. in crores :- 27.50; Expenditure incurred up to 31.12.2006 Rs. in crores :- 27.49, (3) Proposed utilization as per prospectus :- Public Issue Expenses; Estimated cost Rs. in crores:- 7.89; Expenditure incurred up to 31.12.2006 Rs. in crores :- 7.26. Sub-Total :- Estimated cost Rs. in crores :- 152.56; Expenditure incurred up to 31.12.2006 Rs. in crores :- 68.23. (4) Less : Interest earned on fixed deposits kept with bank out of IPO proceeds (Gross including TDS). :- Estimated cost Rs. in crores :- 0; Expenditure incurred up to 31.12.2006 Rs. in crores :- 2.89.Total :- Estimated cost Rs. in crores :- 152.56; Expenditure incurred up to 31.12.2006 Rs. in crores :- 65.34. The unutilized amount of IPO proceed has been kept in fixed deposit with banks

    • 10 Jan · Board meeting

      To consider and approve and take on record the Quarterly Unaudited Financial Results of the Company for the quarter ended on 31st December, 2006 and any other matter with the permission of Chair.

    • 5 Jan · Management

      Meeting of the Board of Directors of the company was held on 28th December, 2006 and following major business were transacted during the course of such meeting - Noting of acceptance of resignation of Mr. Rakesh Jain from the Board of Director of the Company w.e.f 05th December, 2006.

    • 4 Jan · News Verification

      News Verification : The media had reports that Plethico Pharmaceuticals Limited plans to acquire a contract manufacturing company and a retail pharmacy chain in the US. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Plethico Pharmaceuticals Limited has vide its letter inter-alia stated, "We would like to confirm that the news is absolutely correct as the company is pursuing many proposals related to the acquisition of Retail Pharmacy Chain, Manufacturing Unit, OTC Brands, Marketing Firms etc abroad enabling the company to enter in the regulated US and European Markets. The talks on such proposals are at an advanced stage and we are negotiating with the parties for the better rates. The Board of Directors at its meeting held on December 28, 2006 passed suitable resolution to pursue all such proposals to secure healthy growth for the company."

    • 4 Jan · News Verification

      News Verification : The media had reports that Plethico Pharmaceuticals Limited plans to acquire a contract manufacturing company and a retail pharmacy chain in the US. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Reply is awaited from Plethico Pharmaceuticals Limited.